Back to catalogue
POLB

Poolbeg Pharma PLC

Health Care First-pass screen £31m
380/1000 Overall fit
AI beneficiary 35% 38
Operating leverage 25% 30
Valuation 25% 30
Downside protection 15% 64

First-pass take

Clinical-stage infectious disease biotech with early OneThree AI-RSV partnership but zero revenue. Strong net-cash position (£20.9m) provides downside protection, but pre-revenue status, ~£3m annual burn, and micro-cap volatility limit upside within stockemon's AI-exposure and operating-leverage framework.

Flags

loss-makingclinical-stagemicro-capnet-cashai-partnershipno-valuation-datalock-in-overhang